drugset
drugset / Trial / NCT00958074

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

NCT00958074 ↗

Phase 2 Terminated 11 enrolled University of Washington National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Timeline

Start
2009-07
Primary completion
2013-02
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 200 mg Oral
Subject Vorinostat Small molecule 400 mg Oral
Subject Vorinostat Small molecule 500 mg Oral

Indications

primary cutaneous T-cell lymphoma